Shares of Nektar Therapeutics (NASDAQ:NKTR) have received an average recommendation of “Buy” from the nine research firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $26.29.

NKTR has been the subject of several analyst reports. Aegis reiterated a “buy” rating and issued a $21.00 price target on shares of Nektar Therapeutics in a report on Thursday, March 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $17.00 price target (up from $15.00) on shares of Nektar Therapeutics in a report on Friday, March 3rd. Roth Capital set a $23.00 price target on Nektar Therapeutics and gave the company a “buy” rating in a report on Saturday, March 4th. J P Morgan Chase & Co set a $24.00 price target on Nektar Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 21st. Finally, BTIG Research boosted their price target on Nektar Therapeutics from $22.00 to $27.00 and gave the company a “positive” rating in a report on Tuesday, March 21st.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/16/nektar-therapeutics-nktr-receives-average-rating-of-buy-from-analysts.html.

In other news, SVP Jillian B. Thomsen sold 112,500 shares of the company’s stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $19.69, for a total value of $2,215,125.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Maninder Hora sold 180,000 shares of the company’s stock in a transaction dated Wednesday, April 5th. The shares were sold at an average price of $21.70, for a total transaction of $3,906,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 340,914 shares of company stock valued at $7,103,119. 6.10% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the stock. Flinton Capital Management LLC raised its stake in shares of Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 448 shares during the period. State of Alaska Department of Revenue raised its stake in shares of Nektar Therapeutics by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 17,050 shares of the biopharmaceutical company’s stock worth $400,000 after buying an additional 460 shares during the period. Municipal Employees Retirement System of Michigan raised its stake in shares of Nektar Therapeutics by 1.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 34,920 shares of the biopharmaceutical company’s stock worth $820,000 after buying an additional 570 shares during the period. Meadow Creek Investment Management LLC raised its stake in shares of Nektar Therapeutics by 11.1% in the first quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 616 shares during the period. Finally, Glen Harbor Capital Management LLC raised its stake in shares of Nektar Therapeutics by 11.1% in the first quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 784 shares during the period. Institutional investors and hedge funds own 94.02% of the company’s stock.

Shares of Nektar Therapeutics (NASDAQ NKTR) traded up 0.06% on Friday, reaching $18.10. The company had a trading volume of 347,876 shares. The firm has a 50-day moving average price of $19.19 and a 200 day moving average price of $16.19. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $24.88. The firm’s market capitalization is $2.81 billion.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by $0.02. The business had revenue of $24.73 million during the quarter, compared to analyst estimates of $29.43 million. Nektar Therapeutics had a negative net margin of 150.74% and a negative return on equity of 3,072.86%. The company’s revenue was down 58.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.14) earnings per share. Equities research analysts predict that Nektar Therapeutics will post ($1.19) earnings per share for the current year.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.